Business UpdateApr 14, 2026, 08:46 AM
Pelthos Therapeutics Details Product Portfolio & Launch Plans
AI Summary
Pelthos Therapeutics Inc. presented its corporate overview, highlighting its focus as a commercial biopharmaceutical company on a growing, differentiated cutaneous infections product portfolio. The company emphasized its synergistic product acquisitions, Xepi and Xeglyze, which leverage existing commercial infrastructure. Pelthos anticipates strong potential revenue streams and outlined plans for new product launches in late 2026 and the first half of 2027, targeting significant addressable markets.
Key Highlights
- Xepi launched July 2025 with a wholesale acquisition cost (WAC) of $2,008.50.
- Another product launch is expected in late 2026.
- A third product launch is anticipated in the first half of 2027, targeting 6-12 million U.S. cases annually.
- Company stock price was $24.00 with 8.9 million shares outstanding as of March 16, 2026.
Price Impact
More from PTHS